SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

5/5/22 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SCYX alert in real time by email

JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2022.

Conference call and webcast details:

Investors (domestic): (877) 704-4453

Investors (international): (201) 389-0920

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1543196&tp_key=e943d8c4f4

Conference ID: 13729053

A live audio webcast can be accessed by visiting the Investor Relations section of the Company's website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company's lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME ^® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, investigation and development of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (646) 970-4681

[email protected]

Media Relations

Brett Whelan

LifeSci Communications

Tel: (339) 368-0466

[email protected]

Get the next $SCYX alert in real time by email

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

Chat with this insight

Recent Analyst Ratings for
$SCYX

$SCYX
Press Releases

Fastest customizable press release news feed in the world

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

$SCYX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

$SCYX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

$SCYX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

Chat with this insight

Recent Analyst Ratings for $SCYX

$SCYX Press Releases

Fastest customizable press release news feed in the world

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

$SCYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

$SCYX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

$SCYX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

Recent Analyst Ratings for
$SCYX

$SCYX
Press Releases

$SCYX
Insider Trading

$SCYX
Insider Purchases

$SCYX
FDA approvals